What is Jenburkt Pharmaceuticals Ltd (524731) share price return in the past 10 years?

Jenburkt Pharmaceuticals Ltd share price has appreciated 11.1% annually (CAGR) over the past ten years.

What is the share price of Jenburkt Pharmaceuticals Ltd (524731)?

Company share prices are keep on changing according to the market conditions. The current trading price of Jenburkt Pharmaceuticals Ltd (524731) on 04-Jun-2026 16:59:59 at 16:59 is 1123.50.

What is the P/E ratio of Jenburkt Pharmaceuticals?

The latest standalone P/E ratio of Jenburkt Pharmaceuticals as of 04-Jun-2026 is 14.27.

What is the P/B ratio of Jenburkt Pharmaceuticals Ltd (524731)?

The latest standalone P/B ratio of Jenburkt Pharmaceuticals Ltd (524731) as of 04-Jun-2026 is 2.52.

What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd (524731)?

The 52-week high of Jenburkt Pharmaceuticals Ltd (524731) is Rs. 1410.00 and the 52-week low is Rs. 944.00.

Jenburkt Pharmaceuticals Ltd (524731) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Jenburkt Pharmaceuticals Ltd (524731)
Brand: Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Ltd (524731)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524731 NSE: Pharmaceuticals & Drugs | Small Cap | Jenburkt Pharma Share Price

Jenburkt Pharmaceuticals Ltd (524731)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524731 NSE: Pharmaceuticals & Drugs | Small Cap | Jenburkt Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹496 Cr.

Current Price

₹1,123.5

52-Week Low / High

₹944 / 1,410

TTM EPS

₹78.7

TTM Sales

₹169 Cr.

Book Value per Share

₹446.5

P/E Ratio

14.27

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

2.52

In line with its 5-year historical median

Price to Sales (P/S)

2.94

Higher than its 5-year historical median

EV/EBITDA

8.19

Higher than its 5-year historical median

Dividend Yield

1.78%

Profitability Efficiency

Return on Equity (ROE)

20.25%

Outperforms industry median

Return on Capital Employed (ROCE)

27.85%

Outperforms industry median

Return on Assets (ROA)

17.86%

Operating Profit Margin

26.6%

Net Profit Margin

21.14%

Gross Profit Margin

30.8%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

6.85%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

21.95%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

23.4%

Asset Quality

Promoter Holding

46.64%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹193 Cr.

Equity

₹4.4 Cr.

Face Value

₹10

All Time Low / High

₹1.80 / 1410.00

Jenburkt Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Somewhat Overvalued

Check Valuation charts

Price Trend

Weak

Check Price chart

Q.1 Is Jenburkt Pharmaceuticals Ltd a good quality company?

Jenburkt Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Jenburkt Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Jenburkt Pharmaceuticals Ltd vs industry peers?

Jenburkt Pharmaceuticals Ltd revenue CAGR is 4.99%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Jenburkt Pharmaceuticals Ltd?

Promoters hold 46.64% of the Jenburkt Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Jenburkt Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 9.8% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	40.2%	39.3%	42%	36.9%	25.7%	23.8%	26.9%	26.8%	26.3%	27.9%	-
Value Creation Index ⓘ	1.9	1.8	2.0	1.6	0.8	0.7	0.9	0.9	0.9	1.0	-
Growth Parameters ⓘ
Sales ⓘ	93.6	103	115	123	119	109	124	137	142	152	169
Sales YoY Gr.	-	10.4%	11%	7%	-3.1%	-8.1%	13.4%	10.3%	3.8%	6.9%	-
Adj EPS ⓘ	22.9	28.9	36.9	43.2	31.8	35.6	47.9	54.4	58.3	71.9	78.7
YoY Gr.	-	26.3%	27.7%	17%	-26.3%	11.8%	34.5%	13.6%	7.2%	23.2%	-
BVPS (₹) ⓘ	86.4	117.1	133.5	168.8	174.3	214.6	255.8	277.3	328.4	389.2	446.5
Adj Net Profit ⓘ	10.6	13.4	17	19.8	14.6	16.3	22	24	25.7	31.7	35
Cash Flow from Ops. ⓘ	7.8	10	16.2	13	15	19.5	9.3	17.1	8.1	27.9	-
Debt/CF from Ops. ⓘ	0.7	0.6	0	0.6	0.2	0.2	0.6	0.1	0	0.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.5%	5%	7%	6.9%
Adj EPS ⓘ	13.6%	17.7%	14.5%	23.2%
BVPSⓘ	18.2%	17.4%	15%	18.5%
Share Price	11.1%	16.9%	13.9%	-15.1%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	28.9	28.4	29.3	28.6	18.6	18.3	20.4	20	19.3	20	18.8
Op. Profit Mgn % ⓘ	17.6	19.1	20.7	20.4	16.6	18.2	22	22.2	23.3	26.6	25.9
Net Profit Mgn % ⓘ	11.4	13	14.8	16.2	12.3	15	17.7	17.6	18.1	20.9	20.6
Debt to Equity ⓘ	0.1	0.1	0	0.1	0	0	0.1	0	0	0	0
Working Cap Days ⓘ	71	65	69	84	101	129	177	185	156	182	70
Cash Conv. Cycle ⓘ	38	37	39	56	71	62	46	41	45	42	48

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	94	103	115	123	119	109	124	137	142	152
Operating Expenses ⓘ +	77	84	91	98	99	89	97	106	109	111
Manufacturing Costs	5	4	5	5	5	4	6	7	7	6
Material Costs	25	28	31	33	30	28	27	29	27	26
Employee Cost	21	25	28	31	37	32	36	39	42	46
Other Costs ⓘ	25	26	27	28	28	25	26	32	33	34
Operating Profit ⓘ	16	20	24	25	20	20	27	30	33	40
Operating Profit Margin (%)	17.6%	19.1%	20.7%	20.3%	16.6%	18.2%	22.0%	22.2%	23.3%	26.6%
Other Income ⓘ +	3	3	3	3	4	4	5	5	5	7
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	0	1	0	0	0	0	0
Depreciation ⓘ	2	2	2	1	2	2	2	2	2	3
Profit Before Tax ⓘ	17	20	25	27	21	22	30	33	35	44
Tax ⓘ	6	7	8	7	6	5	8	8	9	12
Profit After Tax	11	14	17	20	15	17	22	25	26	32
PAT Margin (%)	11.5%	13.1%	15.0%	16.1%	12.5%	15.1%	18.0%	18.0%	18.3%	21.1%
Adjusted EPS (₹)	23.2	29.1	37.5	43.1	32.4	36.0	48.6	55.8	58.9	72.7
Dividend Payout Ratio (%)	31.10%	27.90%	24%	23.60%	25%	28.40%	24.70%	25.80%	26%	24.80%

Valuation of Jenburkt Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	40	54	61	77	80	98	117	122	145	172
Share Capital ⓘ	5	5	5	5	5	5	5	4	4	4
Reserves ⓘ	36	50	57	73	75	94	113	118	141	167
Debt +	5	6	0	7	3	4	6	2	0	2
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	5	6	0	7	3	4	6	2	0	2
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	3	6	4	7	5	5	7	6	6	8
Others Liabilities ⓘ	9	10	12	11	16	14	12	10	13	13
Total Liabilities ⓘ	58	76	78	103	104	120	143	141	164	195
Fixed Assets
Net Fixed Assets ⓘ +	12	11	10	10	12	11	11	10	10	15
Gross Block	26	25	26	27	31	32	33	34	34	40
Accumulated Depreciation	13	15	16	17	20	21	22	24	23	26
CWIP ⓘ	0	0	0	1	0	0	0	1	1	40
Investments ⓘ	1	2	5	5	4	7	8	11	17	21
Inventories	8	11	7	10	11	8	10	8	9	9
Trade Receivables	6	9	13	23	18	14	15	17	19	21
Cash Equivalents	30	42	41	52	58	57	49	54	79	25
Others Assets ⓘ	2	2	2	2	2	25	49	40	29	65
Total Assets ⓘ	58	76	78	103	104	120	143	141	164	195

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	8	10	16	13	15	19	9	17	8	28
PBT ⓘ	17	20	25	27	21	22	30	33	35	44
Adjustment ⓘ	-1	-1	-2	-2	-1	-2	-2	-2	-0	-3
Changes in Working Capital ⓘ	-3	-3	1	-5	1	5	-11	-6	-18	0
Tax Paid ⓘ	-6	-7	-8	-7	-5	-6	-8	-8	-8	-13
Cash Flow From Investing Activity ⓘ +	-0	-10	1	-11	-3	-19	-1	3	-1	-17
Capex	-2	-0	-0	-2	-4	-1	-3	-2	-3	-20
Net Investments	-0	32	-2	-11	-2	-21	-4	3	-4	-3
Others ⓘ	3	-41	3	3	2	4	5	2	6	5
Cash Flow From Financing Activity ⓘ +	-5	1	-18	-2	-11	-1	-6	-21	-7	-8
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-0	-0	-0	-0	-1	-0	-0	-1	-0	-0
Dividend Paid ⓘ	-3	0	-7	-1	-9	0	-5	-5	-6	-7
Others ⓘ	-2	1	-11	-1	-2	-1	-1	-15	-1	-1
Net Cash Flow ⓘ	2	1	-1	0	1	-0	3	-1	0	3

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	29.28	28.55	29.75	28.54	18.89	18.49	20.66	20.53	19.43	20.25
ROCE (%)	40.17	39.26	41.99	36.9	25.73	23.83	26.89	26.8	26.28	27.85
Asset Turnover Ratio	1.6	1.56	1.49	1.36	1.15	0.97	0.94	0.96	0.93	0.84
PAT to CFO Conversion(x)	0.73	0.71	0.94	0.65	1	1.12	0.41	0.68	0.31	0.88
Working Capital Days
Receivable Days	25.30	25.80	34.30	52.70	62.50	53.20	43	42.90	46.80	48.40
Inventory Days	30.40	33	27.90	24.80	31.80	30.90	25.70	24.30	21.70	21
Payable Days	51.10	61.10	59.30	58.80	71.50	64.60	77.80	84.40	84.80	101.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Jenburkt Pharmaceuticals Ltd FAQs

The current trading price of Jenburkt Pharma on 04-Jun-2026 16:59 is ₹1,123.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Jenburkt Pharma stood at ₹495.8 Cr

The latest P/E ratio of Jenburkt Pharma as of 03-Jun-2026 is 14.27.

The latest P/B ratio of Jenburkt Pharma as of 03-Jun-2026 is 2.52.

The 52-week high of Jenburkt Pharma is ₹1,410 and the 52-week low is ₹944.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jenburkt Pharma is ₹169 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jenburkt Pharmaceuticals Ltd is a good quality company.

The key valuation ratios of Jenburkt Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Jenburkt Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta

Jenburkt is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Jenburkt is a public limited company, with its stock listed on the Bombay Stock Exchange. Jenburkt's headquarters are ocated in Mumbai, from where itâ€™s entire operations

The company has a state-of-the-art manufacturing plants at Sihor-Gujarat,in India. The plant is modern and well equipped with spacious operational areas having adequate capacities for manufacturing world-class pharmaceutical and healthcare products.

The plant is approved as per WHO guidelines for compliances with current GMPrequirements, apart from approvals from various countries.

Jenburkt, has 25 superstockists located in different corners of India, it has approximately 1000 stockists, who buy from Superstockist and sell to chemists. Jenburkt also caters to large government, semi-government institutions, missionary hospitals, public sector enterprises, etc.

Product range of the company includes:

Consumer Division:

Nocal Tablets
Nocal Sachet
Nocal Granular

Pharmaceutical Division:

Anti-Arthritic
Antibiotics
Anti-Diabetic
Nutraceuticals
Anti-Inflammory Analgesics
Gastro Intenstinal
Dermatologicals
Aphrodisiac
Anti-Osteoporotic
Anti-Cough, Cold & Allergy
Anti-Ulcerants

Awards

2010 - The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2011 - The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST"awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates ""Highest performance capability and High financial strength".

Jenburkt Pharmaceuticals Ltd (524731)

Jenburkt Pharmaceuticals Ltd (524731)

Jenburkt Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Jenburkt Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Jenburkt Pharmaceuticals Ltd FAQs

About Jenburkt Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Jenburkt Pharmaceuticals Ltd (524731)

Jenburkt Pharmaceuticals Ltd (524731)

Jenburkt Pharmaceuticals stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Jenburkt Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Jenburkt Pharmaceuticals Ltd FAQs

What is the share price of Jenburkt Pharma?

What is the market cap of Jenburkt Pharma?

What is the P/E ratio of Jenburkt Pharma?

What is the P/B ratio of Jenburkt Pharma?

What is the 52-week high and low of Jenburkt Pharma?

What is the TTM revenue of Jenburkt Pharma?

Is Jenburkt Pharmaceuticals Ltd a good quality company?

Is Jenburkt Pharmaceuticals Ltd undervalued or overvalued?

Is Jenburkt Pharmaceuticals Ltd a good buy now?

About Jenburkt Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.